A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array

European Journal of Human Genetics

Volumn 21, Issue 7, 2013, Pages 779-783

  Gaunt, Tom R ^a   Lowe, Gordon D O ^b   Lawlor, Debbie A ^a   Casas, Juan Pablo ^c,d   Day, Ian N M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

aPTT; coagulation; genotype; SNP

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; G PROTEIN COUPLED RECEPTOR KINASE 6; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; KALLIKREIN; KININOGEN; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; CHROMOSOME 3; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; PARTIAL THROMBOPLASTIN TIME; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVATED PROTEIN C RESISTANCE; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS, INHERITED; FACTOR V; FACTOR XII; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPING TECHNIQUES; HUMANS; KALLIKREINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARTIAL THROMBOPLASTIN TIME; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN C; THROMBOPLASTIN;

EID: 84879421584     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.242     Document Type: Article

References (28)

1. Lowe GDO: Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol 2006; 133: 232-250.
2. Abdullah WZ, Moufak SK, Yusof Z, Mohamad MS, Kamarul IM: Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event. Tr a n s l R e s 2010; 155: 315-319.
3. Lowe GD, Haverkate F, Thompson SG et al: Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999; 81: 879-886.
4. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM: A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104: 3631-3634.
5. Korte W, Clarke S, Lefkowitz JB: Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000; 113: 123-127.
6. Alving BM, Baldwin PE, Richards RL, Jackson BJ: The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb Haemost 1985; 54: 709-712.
7. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
8. De Stefano V, Leone G: Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica 1995; 80: 344-356.
9. Dahlbäck B, Hildebrand B: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400.
10. Warren DM, Soria JM, Souto JC et al: Heritability of hemostasis phenotypes and their correlation with type 2 diabetes status in Mexican Americans. Hum Biol 2005; 77: 1-15.
11. Houlihan LM, Davies G, Tenesa A et al: Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010; 86: 626-631.
12. Morange P-E, Oudot-Mellakh T, Cohen W et al: KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood 2011; 117: 3692-3694.
13. Lawlor DA, Day INM, Gaunt TR et al: The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 2004; 5: 17.
14. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
15. Keating BJ, Tischfield S, Murray SS et al: Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008; 3: e3583.
16. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J: Activated protein C resistance and the FV:R506Q mutation in a random population sample-associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-924.
17. Purcell S, Neale B, Todd-Brown K et al: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
18. Akaike H: A new look at the statistical model identification. Automatic Control, IEEE Transactions on 1974; 19: 716-723.
19. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
20. Klarmann D, Eggert C, Geisen C et al: Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents. Transfusion 2010; 50: 1571-1580.
21. Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR: The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-1695.
22. Souto JC, Almasy L, Muñiz-Diaz E et al: Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-2028.
23. Teupser D, Baber R, Ceglarek U et al: Genetic regulation of serum phytosterol levels and risk of coronary artery disease. Circ Cardiovasc Genet 2010; 3: 331-339.
24. Reilly MP, Li M, He J et al: Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377: 383-392.
25. Saito H: Haemostasis & Thrombosis, In Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Edinburgh: Churchill Livingstone, 1994; 289-308.
26. Bertina RM, Koeleman BP, Koster T et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
27. Tsuchida-Straeten N, Ensslen S, Schäfer C et al: Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005; 3: 865-872.
28. Poon IKH, Patel KK, Davis DS, Parish CR, Hulett MD: Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 2011; 117: 2093-2101.